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ABSTRACT
PROINFLAMMATORY CYTOKINES PROMOTE VIRAL REPLICATION AND
CELL CYCLE MEDIATORS IN ARENAVIRUS-INDUCED HEPATITIS
Gretchen E. Holz
November 21, 2016
Lassa virus (LASV) is an arenavirus and causative agent of Lassa fever
(LF), a viral hemorrhagic fever in West Africa for which there is no vaccine.
Lymphocytic choriomeningitis virus (LCMV), is used as a surrogate to mimic
LASV-induced liver pathology. LCMV-WE, not LCMV-ARM, causes disease in
primates and mice characterized by hepatitis, high viral load, hepatocyte
proliferation, and upregulated proliferative triggers (e.g. TNF-α, IL-6 ).

We

hypothesize LCMV-WE induces pathological hepatocyte proliferation via proinflammatory triggers (TNF-α, IL-6) from macrophages, leading to: increased viral
replication, modulated cell cycle, and arrested cell cycle.

RAW 264.7

macrophages and AML-12 hepatocytes, were used as models for liver cells and
infected with LCMV. High LCMV-WE titers in RAW 264.7 resulted in upregulated
TNF-α.

LCMV-WE infection with TNF-α enhanced viral replication and

modulated cell cycle, leading to arrest. Livers of fatal LASV-infected marmosets
also displayed high viral load, IL-6, and upregulated p21, validating cell cycle
arrest as key hepatic event.

Altogether, these results validate AML-12

hepatocytes to study mechanisms of arenavirus-induced hepatitis.
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INTRODUCTION
Arenaviruses and Public Health
Hemorrhagic fever viruses (HFVs) are a diverse group of RNA viruses that
cause severe disease known as viral hemorrhagic fevers (VHFs).

Principal

symptoms of VHFs include fever, vascular system manifestations, multi-organ
failure and sepsis-like cardiovascular collapse.

Members of many prominent

RNA virus families are defined as HFVs, including Arenaviridae, Bunyaviridae,
Filoviridae, Flaviviridae, and Rhabdoviridae, which are responsible for causing
VHFs like Lassa fever, hemorrhagic fever with renal syndrome, Ebola
hemorrhagic fever, Dengue hemorrhagic fever, and Bas-Congo hemorrhagic
fever, respectively. VHFs have a significant impact on public health worldwide
and cause over 100 million infections per year [1].

Though VHFs create a

substantial medical burden, the availability of treatments and vaccines remain
limited, with some notable exceptions for Yellow fever and Argentine
hemorrhagic fever (i.e. Yellow fever 17D vaccine and Candid#1 vaccine). Thus,
given the lack of effective treatment options coupled with the threat of HFVs
being used as biological weapons, the National Institutes of Allergy and
Infectious Disease (NIAID) consider HFVs Category A priority pathogens [2].
While HFVs come from distinct viral families, they share key characteristics,
including similar mechanisms of infection and pathology in their hosts [3-5].
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The Arenaviridae, a fast growing family of rodent-borne viruses, has the
highest number of HFVs with a significant impact on human health in endemic
areas [1, 6].

Researchers recently discovered arenaviruses not only infect

mammals, but they also infect reptiles (i.e. boid snakes) [7-9]. Based on this
discovery, the Arenaviridae family is divided into two genera, Mammarenavirus
and Reptarenavirus [10]. (NOTE: Mammarenaviruses will be colloquially referred
to as “arenaviruses” from this point forward.) Arenaviruses are split into the Old
World (OW) and New World (NW) virus groups based on phylogenetic,
serological, and geographical differences.

The OW viruses (or LASV-LCMV

sero-complex) are mostly found in Africa, with the exception of LCMV, which is
found all over the world. OW arenaviruses include Lassa virus (LASV), Mopeia
virus (MOPV), Lujo virus (LUJV), Ippy virus (IPPYV), Luna virus (LNKV), Mobala
virus (MOBV), Merino Walk virus (MRWV) and lymphocytic choriomeningitis virus
(LCMV) [10].

LCMV is also considered the prototypic arenavirus.

The NW

viruses (or Tacaribe sero-complex) are distributed throughout the Americas and
include important human pathogens that can cause hemorrhagic fever, like Junin
virus, Machupo virus, Guanarito virus, Sabia virus, and Chapare virus. Tacaribe
virus is considered the prototypic NW arenavirus.
The causative agent of Lassa fever (LF), LASV is the most prominent viral
hemorrhagic fever (VHF) in West Africa [11]. LASV has the most influence on
human health of all the HFVs (second to Dengue virus in terms of morbidity),
causing over 300,000 infections per year with 5,000 – 10,000 deaths annually [1,
6, 11]. Though LASV is a neglected tropical pathogen with significant human
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health impact, treatment options for infection and LF disease are severely
lacking. Supportive care including rehydration and attention to symptoms early in
infection can improve patient prognosis. Ribavirin is a broad-spectrum antiviral
drug that can be effective in treating LASV infection, but it must be taken within a
few days of symptom-onset and it causes many adverse effects.

With no

approved vaccines or effective treatments, the World Health Organization urges
that LASV is a severe HFV in need of immediate research attention to facilitate
development of antiviral therapies and interventions.
Humans become infected with LASV mainly by contact with infected rats,
food, or items contaminated with rodent excreta (e.g. feces, urine, etc.) from the
virus’s natural reservoir, Mastomys natalensis, a multimammate rat found in subSahara Africa [11]. Spread of the virus also happens between humans, through
direct contact with contaminated bedding, soiled clothing, or bodily fluids of
infected person. Moreover, hospital-contracted infections also occur [12]. After
initial contact with LASV, LF symptom onset occurs within 2-21 days. Disease
severity can vary from asymptomatic infection to mild LF symptoms early on,
which are similar to those of other common illnesses and include sore throat,
fever, malaise, and headache. Nausea, vomiting, diarrhea, and abdominal pain,
as well as vascular abnormalities (e.g. hemorrhaging found in the mouth, nose,
gastrointestinal tract, and vagina) are associated with progressed LF disease. In
later stages of disease, seizures, coma, tremor, and shock are observed, which
are evident of multi-organ syndrome and can lead to death.
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Arenavirus Molecular Biology
Arenaviruses are enveloped, single-stranded RNA viruses that use a
negative ambisense coding strategy (i.e. one gene segment on each strand is 5’
– 3’ and the other gene segment is 3’ – 5’ and must be replicated before
transcription) [13-16]. The arenavirus genome consists of two segments, large
(L) and small (S), each encoding two proteins. The L segment encodes the L
polymerase protein and the Z matrix protein [15]. The L protein, the RNAdependent RNA polymerase (RdRp) is responsible for transcription of the viral
genome and replication of the virus. The Z protein is a zinc-binding protein that
plays a regulatory part in replicating viral RNA, reviewed in [17]. The S segment
encodes the glycoprotein complex (GPC), which is post-translationally cleaved
into GP1 and GP2, and the nucleoprotein (NP) [18, 19].

GP1 is the viral

attachment protein that interacts with the host cell receptor, and the GP2 is
involved in pH-dependent endocytosis.

Heavily involved in regulating the

processes of transcription and replication of the viral genome, the NP protein is
the most abundant protein in viral particles and in infected cells, as it
encapsidates the viral genome, reviewed in [17].
Arenaviruses enter host cells through a unique pathway, reviewed in [17].
First, the viruses bind their respective receptors on host cells via the GP1 viral
attachment protein and are then internalized into endosomal compartments. The
research described in this thesis focuses on OW arenaviruses, which primarily
use alpha-dystroglycan (α-DG) as the main viral receptor for attachment and
entry into host cells [20]. After binding α-DG, OW arenaviruses enter cells via a
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unique cholesterol-dependent pathway that is independent of clathrin, caveolin,
and actin, but requires microtubules. Upon internalization, LASV and LCMV-WE
have been shown to by-pass early endosomal compartments, thus avoiding
detection by the immune sensors in these compartments, and thus, virus-bound
receptors traffic directly to late endosomes.

In the late endosome, LASV

switches from α-DG to bind lysosome associated membrane protein 1 (LAMP-1)
and fuses with the cell membrane to release viral RNA into the cytoplasm [21].
However, LCMV-ARM fusion with cell membrane does not require switching to
LAMP-1 [21]. Viral fusion occurs at very low pH (i.e. 3.0-5.0). Viral RNA is then
released into cytoplasm after viral membrane fuses with the late endosome. In
the cytoplasm, the viral RNA is transcribed, translated, and the genome is
replicated.

Then lastly, new viral particles, or virions, are assembled at the

plasma membrane, and bud from the host cell with help of the Z matrix protein,
among other viral and cellular proteins.

Arenavirus Infection, Pathology, and Disease
After crossing epithelial barriers at two major entry gates, the respiratory
and gastro-intestinal tracts, arenaviruses primarily infect macrophages and
dendritic cells (DCs) [22, 23]. While they replicate in many tissues, the highest
titers of arenaviruses are detected in the liver, spleen, lymph nodes, and adrenal
glands [24, 25]. Arenaviruses replicate efficiently without killing their host cells.
Efficient replication occurs in the resident macrophages in the liver called,
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Kupffer cells (KCs), and also in macrophages and DCs in the lymph nodes and
spleen.
In the liver environment, KCs and hepatocytes are important targets of
LASV and LCMV infections and these cell types perform vital duties within the
liver [22, 26, 27]. For example, KCs intercept pathogenic material from the blood
of the portal vein that is filtered by the liver. Hepatocytes have a significant role
in liver function, including: metabolizing basic molecules into useful compounds,
producing plasma proteins (e.g. albumin, coagulation factors), and synthesizing
vital immune response proteins (i.e. acute phase, TLRs, inflammatory cytokines,
chemokines and complement).
environment,

including

antigens

The liver is constantly exposed to the
delivered

via

portal

vein

(from

the

gastrointestinal tract) and from hepatic artery (systemic), and must maintain
immune-tolerance, as reviewed in [28]. Yet, it is a delicate balance because
while it must retain immune-suppression toward the constant exposure to gutderived materials, the liver must also retain immune-responsiveness to bloodborne pathogens and microbes that circulate into the liver. Moreover, the liver
plays a significant role in immunity, also reviewed in [28]. The liver is a dynamic
organ in the body characterized by its metabolic and detoxifying abilities, in
addition to balancing immune responsiveness with immune tolerance, which not
only makes it a good target for viral infection, but also a key target involved in
disease progression.
From the liver, lymph nodes, and spleen, arenavirus infection spreads
systemically throughout the body. However, the pathogenesis of LF disease is
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still uncertain because the tissue damage caused by direct infection in the target
tissues is not severe enough to implicate organ failure as the cause of death [24,
25, 29, 30] In fact, death from LF is caused mostly by uncontrolled sepsis-like
terminal cardiovascular shock.
Liver pathology is the prominent finding from fatal LASV infection.

As

described above, the evidence of severe tissue damage and overt pathology in
fatal LF disease is infrequent and not extensive; however, the histological
abnormalities that are observed during fatal LF are the most pronounced in the
liver, which include multifocal necrosis and areas of hepatocyte proliferation [25,
29]. To this end, healthcare workers described the first clinical cases of fatal
Lassa fever as “Lassa virus hepatitis” [29].

High levels of serum aspartate

aminotransferase (AST), which is commonly used in conjunction with alanine
aminotransferase (ALT) levels as biomarkers of liver health, are hallmarks of
LASV infection [25, 29].

Furthermore, serum AST levels above 120 IU/L in

hospitalized patients were shown to correlate with poor prognosis. Johnson KM
et al. also found that viremia, or uncontrolled systemic infection, was associated
with fatal LASV infection; but progressive control of viremia was found in
survivors of LASV infection [24].

These studies concluded there is a key

correlation between serum levels of ASTs and viremia, and the prognosis of the
patient. Patients with viremia and ASTs below 150 IU/L, were more likely to
survive infection. However, patients with viremia (>3 log TCID50/mL) and ASTs
greater than 150 IU/L, were more likely to die from LF disease. Past research
from cases of human LASV infection has also shown pathological hepatocyte
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proliferation in liver tissue [25, 29, 30].

Fatal Lassa fever patients showed

evidence of LASV replication in hepatocytes [29, 30], evidence of mitosis [25],
and liver damage and regeneration, with three progressive and distinct phases:
1) active hepatocyte injury, 2) continued damage and early recovery, and 3)
hepatocyte regeneration [29]. Thus, while damage to other tissues besides the
liver can also contribute to elevated AST levels, altogether, it is clear that liver
pathology characterized by hepatocellular damage and proliferation plays an
important role in LF pathogenesis and is linked to uncontrolled viral replication.
However, mechanisms behind the disease pathogenesis and liver
pathology caused by LASV are poorly understood.

Moreover, LASV is a

biosafety level 4 pathogen requiring high containment research facilities, which
are found in limited locations in the United States.

Thus, the prototypic

arenavirus, LCMV, has been shown to mimic LASV-induced liver pathology when
used as a surrogate virus in experimental models, reviewed in [31]. LCMV is a
well-studied virus in research models, including in vivo and in vitro models of
infection. Studies of LCMV infection in mice has provided an understanding of
basic concepts in immunology, like acute versus persistent viral infection, MHC
restriction, T cell memory, T cell exhaustion, among other important
immunological concepts [13, 32-35]. The in vitro experiments described in this
thesis use two different strains of LCMV, LCMV-WE (strain 54) and LCMV-ARM
strain 53b). LCMV-WE is the viscerotropic strain known for its tropism to the liver
and virulence in non-human primates (NHPs) [26, 36], guinea pigs [14], and also
liver tropism is documented in mice [37].
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In fact, previous studies showed

LCMV-WE infection in experimental NHP models induced a fatal LF-like disease
characterized by liver dysfunction and robust hepatocyte proliferation [26, 38].
LCMV-ARM, highly adopted to mice and tissue culture, is a neurotropic strain.
Though it shares 88% amino acid homology with LCMV-WE [39], LCMV-ARM
strain does not induce disease in NHPs nor exhibit tropism to the liver in NHPs,
guinea pigs, and mice. Therefore, LCMV-ARM is a good control against the liver
pathology induced by LCMV-WE.
NHPs infected with arenaviruses further demonstrate the critical
importance of the liver during infection. Previous outbreaks of LCMV infection in
zoo-kept New World primates (e.g. marmosets, tamarins) provide further
evidence of targeting the liver. Tamarins and marmosets housed in zoos in
North America and Germany were inadvertently fed newborn mice infected with
LCMV, which caused a severe and fatal infection in the monkeys called
Callitrichid hepatitis [40, 41].

The histopathological observations showed

extensive hepatitis in the livers of fatally-infected monkeys. Also, studies showed
that experimentally-infected NHPs with LASV and LCMV-WE succumbed to a
severe, LF-like disease.

Though histopathology in liver showed only spotty

hepatocellular

and

necrosis

mild

inflammation,

severe

infections

were

characterized by high viremia (>10^5 PFU/mL), interleukin 6 (IL-6), and soluble
IL-6 and TNF receptors in plasma, and also liver pathology that included high
levels (>5-fold) of AST and ALT enzymes, hepatocyte proliferation and liver
dysfunction [26, 27, 36, 38, 42, 43]. LASV and LCMV-WE infections in NHPs
demonstrated that KCs and hepatocytes were also clear targets of infection.
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Showing viral antigens in both cells, which populate the majority of the liver,
lends more detailed support to data revealing the livers had the highest viral load
all of tissues during terminal illness [26, 27, 43].
Furthermore, experimentally LCMV-infected mice represent a welldocumented model capable of demonstrating clear differences in tropism; as
LCMV-WE causes transient hepatitis, while LCMV-ARM does not.

Similar

characteristics of liver pathology found with LCMV-WE infection in NHPs also
have been noted in mice: elevated liver enzymes (AST, ALT) in plasma, viremia,
and histopathology detailing spotty necrosis, mild inflammation, induction of
hepatocyte proliferation, and elevated gene expression for tumor necrosis factor
alpha (TNF-α)

[37, 44, 45].

Furthermore, although KCs or resident liver

macrophages were targeted early, hepatitis developed when hepatocytes were
targeted more exclusively later in infection [44]. We previously observed in mice
that LCMV-WE caused transient hepatitis and liver pathology characterized by
robust hepatocyte proliferation without hyperplasia, cell cycle arrest, and strong
upregulation of hepatic tumor necrosis factor alpha (TNF-α) expression [45].
Notably, while IL-6 was shown to be a key biomarker of severe infection in NHPs,
TNF-α, however, was an important pro-inflammatory signal robustly upregulated
in the livers of mice infected with LCMV-WE.
Collectively, our results proposed a novel mechanism of arenavirusinduced liver pathology in which activation of hepatocyte proliferation resulted in
arrested cell cycle and down-stream events (e.g., IFN-gamma up-regulation,
apoptosis, oval cell activation), further contributing to the pathogenesis of
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arenavirus-induced hepatitis. These findings of cell cycle arrest were novel and
highly intriguing, bringing about more questions concerning viral mechanisms: is
cell cycle arrest a true viral mechanism or is it an artifact of using a murine
model?

Cell Cycling Modulation, a Common Strategy in Viral Replication
Manipulating host cell cycle for viral benefit is a commonly employed
pathogenic mechanism for RNA viruses. Several RNA viruses have been shown
to manipulate cell cycle mediators and movement through the first gap phase
(G1) to increase viral replication [46-50]. Progression through G1 is controlled by
phosphorylation of retinoblastoma protein (pRb) via binding of D-type cyclins and
cyclin-dependent kinases (CDK) 4 and 6 complex. Movement into and through S
phase is associated with increasing levels of cyclins A and E, with both cyclins
forming complexes with CDK2 to further phosphorylate pRb, reviewed in [51].
Furthermore, enhanced viral replication and viral proteins have also been
correlated with accumulation of markers for cell cycle arrest, like tumor
suppressor protein p53 and CDK inhibitor (CKI) p21. The active form of p53 is
responsible for, among other effects, initiating the transcription of p21, reviewed
in [51]. An important inhibitor of G1/S phase transition, p21 is a CKI that binds to
and inhibits activity of CDK2-cyclin E complex, which inhibits cell cycle
progression to S phase, resulting in cell cycle arrest, reviewed in [52]. While
there is evidence of other RNA viruses’ manipulation of cell cycle at G 1 phase,
OW arenaviruses use a very unique mechanism of manipulating cell cycle. They

11

first induce pathological cell cycle in hepatocytes, and then subsequently inhibit
cycling by inducing cell cycle arrest. This unique mechanism is examined in this
thesis using in vitro hepatocytes. Along with this mechanism, a non-conventional
receptor for viral entry into host cells, Axl, was examined to determine altered cell
cycle effects on gene expression of known entry factor for the virus. Given the
reproducibility, and molecular evidence of cell cycle modulation during arenavirus
infection, we propose that cell cycle modulation is a key facet of arenavirus
replication.

Arenavirus Infection Induces Cytokine Expression
Pro-inflammatory

cytokines

and

receptors

involved

in

triggering

hepatocyte proliferation are found to be upregulated in the livers and plasma of
human LASV and experimental LCMV-WE infections [26, 27, 43, 53].
Hepatocyte proliferation is a highly conserved and coordinated sequence of
events generally reserved for repairing a severely damaged liver—from partial
surgical removal, hepatic toxins, or infection. While hepatocytes do not cycle or
divide under normal circumstances, they have the ability to undergo cell cycle in
response to specific signals, reviewed in [54]. KCs are responsible for producing
cytokines, including pro-inflammatory TNF-α and IL-6, which are important
signals involved in the “priming phase” of preparing hepatocytes to respond to
growth factors that trigger proliferation after liver injury [55-57].

Liver

regeneration studies have indicated production of these cytokines is stimulated
by lipopolysaccharide (LPS) coming from the enteric system and binding its toll-
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like receptor (TLR) on KCs [58-60].

In contrast, other research suggests

signaling through the LPS receptor on KCs--TLR4 and TLR2—are not required
for production of pro-inflammatory signals needed for liver regeneration [61].
Importantly, therefore, it is clear that significant liver damage is a trigger
necessitating the highly-coordinated and timely events that result in liver
regeneration.
Therefore, it is poorly understood why or how LASV and LCMV-WE
infections stimulate such robust hepatocyte proliferation responses in livers
displaying only spotty necrosis and mild inflammation. It is evident, as previously
mentioned, that infection produces high levels of IL-6 and receptors for TNF-α
and IL-6 in circulation and in the liver.

As the main producers of pro-

inflammatory cytokines in the liver and target of LASV and LCMV-WE, KCs are
potentially the source of transient TNF-α and IL-6 responsible for triggering
pathological hepatocyte proliferation.

While research has shown LASV and

LCMV-WE infection is immune-suppressive in macrophages [22, 26, 62, 63], the
timing and concentration of pro-inflammatory cytokines are two important factors
that can lead to profoundly different outcomes, reviewed in [64, 65]. In fact, TNFα levels are increased transiently after surgical partial hepatectomy [56, 66, 67]
and its “priming” effects on preparing hepatocytes for proliferation are gone after
48 hrs [60].

In the liver, varying TNF-α levels can stimulate cell apoptosis,

cytokine production, and proliferation [68].

In this thesis, pro-inflammatory

responses are assessed after LCMV infection in macrophages in vitro to
determine OW arenavirus’s ability to directly trigger proliferative cytokines.
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The objective of this work is using in vitro models to investigate the
mechanisms involved in arenavirus-induced pathological hepatocyte proliferation.
We show evidence that viral replication in macrophages induces proinflammatory cytokines involved in hepatocyte proliferation.

Furthermore, we

show that TNF-α stimulation along with LCMV-WE infection of hepatocytes
results in enhanced viral replication and manipulation of cell cycle with evidence
of cell cycle arrest. Lastly, these in vitro findings were generally supported in an
in vivo model. Liver tissue from marmosets fatally-infected with LASV displayed
robust elevation of pro-inflammatory cytokine associated with hepatocyte
proliferation, high viral load, and upregulation of cell cycle inhibitor suggestive of
cell cycle arrest.
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MATERIALS AND METHODS
A. Cell culture, materials, and virus. RAW 264.7 murine macrophages (ATCC,
TIB-71), AML-12 murine hepatocytes (ATCC, CRL-2254), and Vero E6 cells
monkey kidney cells (ATCC, CRL-1586) were purchased from ATCC. RAW
264.7, mouse leukaemic macrophage cells, and Vero E6, African green monkey
kidney epithelial cells, were cultured in DMEM/F-12 with L-glutamine, HEPES
(Gibco) supplemented with 10% heat-inactivated FBS and 1% antibioticantimycotic (Gibco). AML-12 cells are non-tumorigenic, murine hepatocytes
isolated from the liver of mice transgenic for human TGF-α [69]. These cells
were cultured in DMEM/F-12 with L-glutamine, HEPES (Gibco) supplemented
with 10% FBS, 1% antibiotic-antimycotic, 0.02% insulin, transferrin, selenium
(ITS), and 40ng/mL dexamethasone. Recombinant mouse TNF-α (R&D
Systems) diluted in serum free DMEM was used at different concentrations for
stimulation of AML-12. LCMV-ARM strain 53b and LCMV-WE strain 54, were
used for infection of all tested cells at a multiplicity of infection (MOI) of 1 PFU
per 10 cells or 0.1 MOI. To make virus stocks: Vero E6 cells were infected with
LCMV-ARM (53b) or LCMV-WE (54) at 1 PFU per 1000 cells for 1 hr at 37°C.
Media used for virus stocks contained 2% FBS. Virus stocks (1 x 107-1 x 108
PFU/mL) were harvested in cell-free media, without detectable levels of
cytokines and stored at -80°C until use.
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B. LCMV growth kinetics. For growth kinetics experiments, cells were seeded
at 2.5 x 105 cells/mL on 12-well plates in normal media and cultured for 1 d.
Before infections, cells were washed twice with cold, serum-free media (SFM)
and then infected with 0.1 MOI LCMV-WE or LCMV-ARM for 1h at 37ºC, with
rocking every 15 min. Mock-infected, control cells were treated with SFM for 1 hr,
rocking every 15 min also. After 1 hr, unattached virus was removed, cells were
washed twice and incubated in maintenance media (DMEM supplemented with
2% FBS and antibiotic-antimycotic) at 37ºC until termination.
C. TNF-α stimulation and LCMV infection in AML-12.

AML-12 cells were

seeded at confluency, 5 x 105 cells/well in 12-well or 4 x 104 cells/well in 96-well
plate and cultured for 1 d in normal media. Cells were then washed twice and
incubated in low serum media (0.5% FBS in DMEM with antibiotic-antimycotic) to
growth arrest/synchronize cells for 2 d (modified protocol from [70]). Cells were
then stimulated with TNF-α (200 ng/mL or otherwise indicated) in SFM for 4 hrs
to initiate priming phase and ready cells for proliferation, with addition of FBS
media. Before infections, cells were washed twice with cold, SFM. Cells were
infected with 0.1 MOI LCMV-WE or LCMV-ARM for 1h at 37ºC, with rocking
every 15 min. Mock-infected and TNF-α-only stimulated cells were treated with
SFM for 1 hr, rocking every 15 min. For experiments with TNF-α, a 5% FBS
media with TNF-α (200 ng/mL or otherwise indicated) was put back on cells until
termination. BrdU cell proliferation assay was performed as indicated below, or
supernatants and cells were collected at indicated time points post-infection for
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plaque assay and RNA isolation, respectively, and stored at -80ºC until further
analysis.
C. Plaque assay. The work described in this thesis uses plaque assay to
quantitate infectious viral particles and determine viral titers. Here is a brief
overview of the plaque assay technique, adapted from Shurtleff et al [71]:
Supernatants collected from infected cells are examined using plaque
assay to determine and quantitate infectious virus. This assay begins with serially
diluting experimental supernatants that contain an unknown concentration of
virus in order to get a countable range of virus particles. Permissive host cells
grown in a monolayer are then inoculated with viral dilutions. Vero cells are
utilized as the host cells for plaque assay to test many different species of
viruses because they are interferon-deficient and do not produce interferon alpha
or beta in response to viral infection [72]. An overlay media containing agarose
or methyl cellulose is put back on cells in order to contain virus infection to
infected and adjacent cells, which will ultimately allow visible plaque formation in
the cell monolayer. The cells are then incubated in this overlay media for 5 days
and then cells are fixed with paraformaldehyde. They are stained with a dye, like
crystal violet or neutral red, which will be taken up by all viable or uninfected
cells. In the case of arenaviruses, this plaque is not due to cell death, but rather
due to altered cell physiology and inability of infected-cells to take up the dye
[31]. Lastly, the visible plaques in the monolayer are counted and then used to
calculate the amount of infectious virus or viral titers from the experimental
sample.
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As mentioned above, plaque assay was used in this work to determine
viral titers of collected supernatants from experimental samples. Vero E6 cells
were seeded at 1.4 x 105 cells/mL in 12-well tissue culture plates and incubated
at 37ºC in 5% CO2 for 48 hr. Cells were washed twice with cold, serum-free
DMEM without phenol and infected with serially-diluted supernatants for 1 hr in a
humidified chamber at 37ºC in 5% CO2, with rocking every 15 min. Cells were
then washed twice with warm culture medium containing 5% FBS. An overlay
solution was applied consisting of 1X minimal essential media, sodium
bicarbonate, glutamine, 2% FBS, and 0.5% agarose. Cells were incubated in a
humidified chamber at 37ºC in 5% CO2 and terminated 5 d later. Cells were fixed
in 4% paraformaldehyde for 20 min at room temperature, then washed twice with
PBS and stained with 0.1% crystal violet in PBS for 20 min at room temperature.
Crystal violet stain was washed out of wells one time with water. Last, plaque
forming units (PFU) per mL were determined: by counting the visible plaques for
each dilution and calculating (avg. # of plaques / volume of inoculum) * dilution
factor = PFU/mL.
D. RNA isolation and Quantitative Reverse Transcription-Polymerase Chain
Reaction. RNA was isolated from in vitro cells by using a phenol and
guanidinium thiocyanate solution (RNA-Stat 60, Tel-Test). Cells were lysed by
directly applying RNA STAT-60 to cells in tissue culture plates.

RNA was

extracted using chloroform and centrifugation to separate RNA from DNA and
protein. Isopropanol was used to precipitate RNA and then washed twice in
ethanol. RNA concentrations were determined spectrophotometrically and 1 µg
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total RNA was reverse-transcribed to make cDNA using a kit (Quanta
Biosciences). The cellular mRNA expression of target genes was determined by
using quantitative reverse-transcription polymerase chain reaction (qRT-PCR).
Primers and probes for Tnf, Il-6, Cdk6, Ccnd1 (cyclin D), tp53 (p53), Cdkn1a
(p21), Axl, and Gapdh (mouse); IL-6, CDKN1A, AXL, and 18S (human); and
CCND1 and TP53 (Rh. macaque) were purchased from Life Technologies. For
list of genes with primer ID’s, see Appendix 2 page 67. All primers span exonexon junctions and ensure that only cDNA and not genomic DNA was amplified.
PCR reaction mix was prepared with TaqMan Fast Advanced Master Mix
(Applied Biosystems). This mixture is optimized for TaqMan reactions and is a
2X concentration containing AmpliTaq Fast DNA Polymerase, Uracil-N
glycosylase, dNTPs with dUTP, and a passive ROX reference.

Amplification

reactions were carried out using the Applied Biosystems Real-Time PCR
StepOnePlus machine and software (Thermo-Scientific) with initial holding stage
(50˚C for 2 min, 95˚C for 20 seconds) and 50 cycles of a 2-step PCR (95˚C for 1
second, 60˚C for 20 seconds).

Fluorescent intensity of each sample was

measured at each cycle to monitor amplification of the target gene. Comparative
CT method was used to determine fold changes in mRNA expression compared
to an endogenous reference gene (Gapdh or 18S). Comparative CT method
determines the amount of target, normalized to an endogenous reference
(Gapdh or 18S) and relative to mock-infected, untreated control (2-ΔΔCT).
For viral RNA determination from marmoset liver tissue, NP-specific primers for
LASV were used for determination of viral RNA load in liver tissue. LASV-NP
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primers were purchased from Life Technologies. For specific primer/probe
sequences see Appendix 2 page 67. All gene expression changes are
normalized to 18S endogenous control and relative to control (#10) marmoset.
E. TNF-α Enzyme-linked immunosorbent assay. Supernatants were collected
every 12 hpi from RAW 264.7 infected with LCMV-WE and LCMV-ARM and were
analyzed for secreted TNF-α. Detection and quantitation of murine TNF-α was
determined using an enzyme-linked immunosorbent assay kit (R&D Systems)
according to manufacturer’s protocol. Samples collected at later time points were
diluted in order to obtain accurate absorbance readings within standard curve
range.
F. Cell proliferation assay using BrdU incorporation. Using a modified
seeding and TNF-stimulation protocol from [70], AML-12 cells were seeded at
confluency, 4 x 104 cells/mL in 96-well plate and cultured for 1 d in normal AML12 media. Cells were washed 2X and changed to low serum media (0.5% FBS in
DMEM with antibiotic-antimycotic) to growth-arrest and synchronize cells in cycle
for 2 d. Cells either received TNF-α (200 ng/mL) in serum free media (SFM) or
only SFM for 4 hr, as a priming phase before growth factors. Media containing
none, 0.5%, or 5% FBS, or 5% FBS + TNF-α was put back on cells for 24 hr.
Using a cell proliferation assay kit (Cell Signaling Technology) that detects 5bromo-2’-deoxyuridine (BrdU) incorporation into cellular DNA, BrdU was added
to supernatant media at 20 hr and allowed to incorporate for 4 hr. Manufacturer’s
protocol was followed. Cells were fixed and DNA denatured using the kit’s
solutions. As a pyrimidine analog BrdU in culture media will incorporate into
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newly synthesized DNA, in place of thymidine, in actively proliferating cells. A
mouse monoclonal antibody (mAb) that detects BrdU was added and then an
anti-mouse secondary antibody linked to an HRP was added to recognize the
mAb. TMB substrate was added lastly, which is cleaved by the HRP and causes
a color change. Proliferation—specifically, cells in S phase of cell cycle—is
directly indicated by amount of BrdU incorporation, which is determined by
magnitude of absorbance of color change.
G. Cell viability assay using Cell Titer Glo. Cells were seeded using the
protocol stated in the cell proliferation assay method, above. Media containing
none, 0.5%, or 5% FBS, or 5% FBS +/- TNF-α was put back on cells for 36 hrs at
0.1mL/well. A Cell Titer Glo (Promega) assay was used to determine cell viability
of AML-12 hepatocytes in different TNF and %FBS conditions. The reagent is
put directly on the cells at a 1:1 ratio of media to reagent (i.e. put on 0.1mL
reagent/well). The reagent lyses the cells and creates luminescent output
proportional to the amount of ATP production from the cells, which ATP
production will be indicative of the number of metabolically active cells. The
luminescent signal can then be quantitated with a luminometer.
H. Statistical analysis. Experiments were performed with technical and
biological replicates (n=3). Student’s t-tests were used to assess significant
differences (P<0.05) for viral replication, gene expression, cytokine production,
and cell proliferation, as indicated in the figures by an asterisk (*). Data are
presented as means ± S.E.M. For viral replication and gene expression analyses
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in Figures 3 and 4, *, P<0.05 comparing LCMV-ARM and TNF-α + LCMV-ARM;
or comparing LCMV-WE and TNF-α + LCMV-WE.
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RESULTS
1. LCMV infects and replicates efficiently in RAW 264.7 macrophages and
AML-12 hepatocytes.
Post-mortem studies of LF patients and experimentally-infected animals
showed critical involvement of liver resident macrophages (KCs) and
hepatocytes in pathogenesis of arenavirus-induced hepatitis [26, 27, 29, 38, 42,
44, 45].

Recently, using mice experimentally-infected with LCMV, we

documented that LCMV-WE, but not LCMV-ARM, induced transient hepatitis
characterized by LCMV-WE infection in KCs and hepatocytes and upregulation
of hepatic TNF-α pro-inflammatory cytokine [45].
To determine the contributions of KCs and hepatocytes in LCMV-induced
hepatitis, we first examined replication kinetics of LCMV-WE and LCMV-ARM in
tissue culture models, RAW 264.7 and AML-12, that mimic KCs and hepatocytes,
respectively (Figure 1). Cells were infected with LCMV-WE and LCMV-ARM at
0.1 MOI and supernatant media was collected every 12 hrs for 48 hrs total for
later plaque assay to analyze infectious virus produced from the cells. A low MOI
was used here and in all experiments in order to see logarithmic growth of the
viruses and to assess the effect of viral replication on host factors over a period
of time.
LCMV replication kinetics were first determined in RAW

264.7

macrophages (Figure 1A). As shown in Figure 1A, both strains of LCMV infected
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Figure 1.
LCMV infects and replicates efficiently in RAW 264.7
macrophages and AML-12 hepatocytes. (A) RAW 264.7 and (B) AML-12 were
infected with LCMV-WE or LCMV-ARM at 0.1 MOI and supernatants were
examined for productive viral replication by plaque titration assay, as described in
Materials and Methods. Limit of detection for viral titer measurement is 100
PFU/mL. Data presented as means ± S.E.M of technical replicates, n=3. *,
indicates significance (P<0.05), using Student’s t-Test, between LCMV-WE and
LCMV-ARM.
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and replicated efficiently in RAW 264.7 macrophages. Growth kinetics of viral
replication from 12-48 hours post-infection (hpi) showed LCMV-WE replicated to
significantly higher titers than LCMV-ARM at each time point. While both viruses
replicated well in these cells, LCMV-WE did so more efficiently, reaching peak
viral titers greater than 10-fold higher than those of LCMV-ARM at 36 hpi and
later.

These growth kinetics results demonstrate that both LCMV-WE and

LCMV-ARM infect and replicate in RAW 264.7 macrophages, with LCMV-WE
replicating to higher titers than LCMV-ARM consistently throughout infection.
As mentioned above, hepatocytes are also important targets of arenavirus
infection, following initial infection in KCs.

To further investigate the role

hepatocytes play in arenavirus-induced liver pathology, we next determined
replication kinetics in AML-12 hepatocytes, using similar conditions and timing as
those described above for RAW 264.7 infection with LCMV. As shown in Figure
1B,

both

LCMV-WE and

LCMV-ARM replicated

efficiently in

AML-12

hepatocytes, with both strains reaching peak viral titers at 48 hpi. LCMV-WE
replicated to significantly higher viral titers compared to LCMV-ARM, about 10fold higher early in infection (12, 16 hpi) and 100-fold higher late in infection (36
hpi).

These growth kinetics data demonstrated AML-12 hepatocytes were

permissive to both LCMV strains and though both LCMV-WE and LCMV-ARM
replicated productively in these cells, LCMV-WE reached significantly higher
titers than LCMV-ARM.
Thus, LCMV growth kinetics in RAW 264.7 macrophages and AML-12
hepatocytes revealed differences between LCMV-WE and LCMV-ARM’s ability to
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replicate in these murine in vitro conditions. The next experiments focused on
determining the impact of these differences in replication abilities on important
host factors, like pro-inflammatory cytokines involved in hepatocyte proliferation.

2. Highly productive replication of LCMV-WE in RAW 264.7 macrophages is
associated with induction of pro-inflammatory cytokines.
Since RAW 264.7 macrophages were indeed permissive to LCMV, we
next examined the impact of LCMV infection on pro-inflammatory cytokines
involved in triggering hepatocyte proliferation, TNF-α and IL-6. Cells from LCMVinfected RAW 264.7 macrophages were collected at the indicated times postinfection and analyzed for gene expression changes in TNF-α and IL-6 (Figure
2A).

Fold mRNA induction of these genes was normalized to Gapdh

(endogenous control) and relative to mock-infected (negative control).

The

relative mRNA levels of Tnf and Il-6 were significantly increased during LCMVWE infection at 36 and 48 hpi, when compared to levels observed in LCMV-ARM
infection. At these times, respectively, LCMV-WE induced Tnf expression 25and 15-fold over mock-infected cells, with LCMV-ARM modestly inducing Tnf at
5- and 3-fold over mock-infected cells. As seen in Figure 2A, Il-6 expression was
upregulated 80-fold greater than mock-infected at 36 hpi and robust Il-6
upregulation was observed at 48 hpi in LCMV-WE-infected cells, exhibiting levels
>2000- fold over mock-infected cells. The effect of LCMV-ARM infection on Il-6
expression at these time points was mild and significantly less than that of
LCMV-WE. Robust differences in Tnf and Il-6 gene expression at 36 and 48 hpi
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Figure 2. Highly productive replication of LCMV-WE in RAW 264.7
macrophages is associated with induction of pro-inflammatory cytokines.
RAW 264.7 were infected with LCMV-WE (red bars) or LCMV-ARM (black bars)
at 0.1 MOI. (A) Cells were collected at indicated times for RNA isolation. cDNA
was made and analyzed for pro-inflammatory cytokines, TNF and IL-6, using
real-time RT-PCR. mRNA levels were graphed as fold mRNA normalized to
Gapdh endogenous control and relative to mock-infected negative controls (not
shown, but are equal to 1-fold), as described in Materials and Methods. (B)
Supernatants were collected at indicated times to evaluate murine TNF-α protein
released from RAW 264.7 cells. A sandwich ELISA kit (R&D Systems) was used
to detect TNF-α protein concentration following manufacturer’s instructions. Data
presented as means ± S.E.M of technical replicates, n=3. *, indicates significance
(P<0.05), using Student’s t-Test, between LCMV-WE and LCMV-ARM.
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also correlated with LCMV-WE peak viral titers, which were greater than 10-fold
over LCMV-ARM titers (Figure 1A).
Furthermore, to determine if these mRNA expression changes translated
to TNF-α protein production, we tested supernatant media from each time point
using an ELISA to detect and quantitate TNF-α released from RAW 264.7
macrophages (Figure 2B). We focused on TNF-α specifically because this proinflammatory cytokine was upregulated in our results from LCMV-WE infection in
mice [45]; therefore, we focused on this cytokine in our murine macrophages
here. As observed in Figure 2B, LCMV-WE-infected cells produced significantly
greater concentrations of TNF-α protein (>4500 pg/mL) at 36 and 48 hpi about
3.5-fold greater than TNF-α produced from cells infected with LCMV-ARM
(<2300 pg/mL). Increases in levels of Tnf mRNA in LCMV-WE-infected cells at
36 and 48 hpi (Figure 2A) were thus confirmed at protein level with significant
increases in TNF-α also produced from these LCMV-WE-infected cells.
However, it was interesting that pronounced differences in TNF-α mRNA
induction between LCMV-WE and LCMV-ARM-infected cells (e.g. 5-fold
difference at 36 hpi) resulted in more subtle, but still obvious, differences in TNFα protein expression. In summary, these results demonstrate that LCMV-WE
infection induced pro-inflammatory cytokines, TNF-α and Il-6, which cytokine
induction was also associated with peak LCMV-WE titers in RAW 264.7
macrophages.
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3. TNF-α induces proliferation without affecting cell viability in growtharrested, confluent AML-12 hepatocytes.
TNF-α is a pleiotropic cytokine responsible for diverse biological effects in
the liver, including apoptosis, survival, and proliferation [68]. One critical role of
TNF-α in the liver, along with IL-6, upon release from KCs is its early involvement
in triggering hepatocyte proliferation [55, 56, 60].

In the remaining in vitro

experiments, we used a supra-physiological concentration of TNF-α at 200
ng/mL to stimulate proliferation of confluent and growth-arrested AML-12
hepatocytes, modified protocol from [70, 73].

This concentration of TNF-α,

however, is greater than our observations of TNF-α produced by LCMV-WEinfected RAW 264.7 macrophages (Figure 2B).
TNF-α can have cytotoxic effects on cells. We first examined AML-12 cell
viability to determine the effect of synchronizing cells in cycle for 2 days in low
serum media per [70] and also the effect of TNF-α on the AML-12 cell viability.
Cell viability was assessed by using an assay to quantitate ATP production
(Figure 3A). Using the same protocol (modified from [70]) for the remaining
experiments, AML-12 hepatocytes were seeded at confluency and subsequently
growth-arrested for 2 days in low-serum 0.5% FBS media. Following growtharrest was a 4 hour TNF-α stimulation to prime the cells to receive subsequent
5% FBS media, and cells were incubated in this media for 36 hours to test cell
viability for the same length of time as later infection experiments lasted. These
confluent, growth-arrested cells in 0.5% FBS were considered the baseline, as
100% viable (dotted line in Figure 3A). All other cell conditions were compared
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Figure 3. TNF-α induces proliferation without affecting cell viability in
growth-arrested, confluent AML-12 hepatocytes. Cells were seeded at
confluency, 4x104 cells/well of a 96-well plate, cultured for 1d, and then changed
to 0.5% FBS media to growth-arrest cells for 2d. Cells were stimulated with 200
ng/mL TNF for 4hrs and then incubated in differing %FBS media. (A) After 36hrs,
AML-12 cell viability was measured with Cell Titer Glo assay (Promega). (B) After
20hrs, cell proliferation was determined using a kit (Cell Signaling Technology).
BrdU was added to AML-12 to incorporate for 4hrs and then supernatant media
removed and cells fixed/denatured. Cell proliferation was determined by amount
of BrdU incorporation into cellular DNA via immuno-detection techniques and
quantitating color change. Data presented as means ± S.E.M of technical
replicates, n=4. *, indicates significance (P<0.05) between no TNF, 5% FBS and
TNF plus 5% FBS; **, indicates significance (P<0.05) between no TNF, 0.5%
FBS and no TNF, 5% FBS; using Student’s t-Test.
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to the viability of these cells, because all AML-12 experiments follow this same
protocol. As determined from cell viability data in Figure 3A, regardless of TNF
treatment, cells that were not released in serum media (the first two bars in the
graph) showed signs of substantial cell death with 50% less viability than growtharrested cells. However, the cells released in either 5% or 10% FBS media with
or without TNF stimulation (last four bars in Figure 3A) showed greater cell
viability than the growth-arrested cells. It is evident from these analyses that
growth-arresting and stimulating AML-12 hepatocytes with TNF-α does not cause
cytotoxicity.
Next, the ability of TNF-α to induce hepatocyte proliferation in these
confluent and growth-arrested AML-12 hepatocytes was determined (Figure 3B).
AML-12 hepatocytes were seeded under the same conditions as the protocol
described above. Growth-arrested cells were stimulated with TNF-α (200 ng/mL)
to prime the hepatocytes, followed by 24 hour incubation in 5% FBS media
containing TNF-α. Proliferation was assessed via the number of cells in S phase
of cell cycle, which was determined using an assay that measured BrdU
incorporation into cells’ newly synthesized DNA. As shown with the first bar in
Figure 3B, the cells growth-arrested or synchronized in 0.5% FBS for 2 days
(baseline), displayed minimal BrdU incorporation, thus minimal cell cycling
activity. Cells that were not released in serum media showed similar or less
BrdU incorporation, regardless of TNF stimulation. Released cells in 5% FBS
media with no TNF stimulation, however, showed significantly more BrdU
incorporation than the synchronized AML-12 hepatocytes. Furthermore, AML-12
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hepatocytes released in 5% FBS media and stimulated with TNF resulted in a
significant increase in BrdU incorporation compared to cells synchronized in
0.5% media and also compared to cells receiving no TNF, but incubated in 5%
FBS media. Thus, TNF stimulation with release in 5% FBS media induced more
proliferation than any other condition. Altogether, these data showed that TNF-α
triggered AML-12 hepatocyte proliferation into S phase, without toxicity to the
cells.

4. TNF-α enhances LCMV-WE replication in AML-12 hepatocytes.
After finding that TNF-α is robustly produced from LCMV-WE infected
macrophages (Figure 2), and TNF-α triggers AML-12 hepatocytes to proliferate
without killing the cells (Figure 3), next we examined the impact of TNF-α on
LCMV infection in AML-12 hepatocytes.
First, the ability of TNF-α to cause virucidal or inhibitory effects on LCMV-WE and
LCMV-ARM was determined.

LCMV-WE and LCMV-ARM virus stocks were

incubated with TNF-α at high (800 ng/mL) and low (12.5 ng/mL) concentrations
for 1 hour at 37°C and then plaque assay was used to assess viral titers.
Virucidal effect was not detected at high or low TNF-α concentrations with either
LCMV strain, as titers were unchanged with the addition of TNF-α (data not
shown).
Confluent, synchronized AML-12 hepatocytes were stimulated with TNF-α
and infected with LCMV to next determine if TNF-α had an impact on LCMV titers
at one time point, 24 hpi. As observed with data shown in Figure 4A, cells
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Figure 4. TNF-α enhances LCMV-WE replication in AML-12 hepatocytes.
Confluent, growth-arrested AML-12 hepatocytes were stimulated with TNF-α
(200 ng/mL) before infection and the cells were incubated in 5% FBS media
containing TNF-α after infection. (A) At 24hpi, supernatants were collected and
analyzed by plaque assay for quantitation of infectious virus production and viral
titers were determined. LCMV-ARM and LCMV-WE titers produced from TNF-αstimulated cells were normalized to LCMV-ARM and LCMV-WE titers,
respectively, produced from unstimulated cell. LCMV titers from unstimulated
cells were considered = 1 and relative increases in LCMV titers with TNF-α
stimulation were quantitated relative to 1. (B) At 12, 24, and 36 hpi supernatants
were collected and analyzed by plaque assay for quantitation of infectious virus
production. Data presented as means ± S.E.M of technical replicates, n=3. *,
indicates significance (P<0.05), using Student’s t-Test, between WE and WE +
TNF-α; or, ARM and ARM + TNF-α.
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stimulated with TNF-α and infected with LCMV-WE produced significantly greater
viral titers, more than 10-fold higher compared to titers produced from LCMV-WE
infection without TNF-α. However, with or without TNF-α stimulation of AML-12
hepatocytes, LCMV-ARM titers were unchanged at 24 hpi. Thus, TNF-α had a
significant impact on LCMV-WE titers at one time point, enhancing titers greater
than 10-fold.
Next, we assessed the impact of TNF-α on viral replication over a 36 hour
time period when exponential viral replication occurs, at 12, 24, and 36 hpi, in
AML-12 hepatocytes. As observed in Figure 4B, in cells stimulated with TNF-α,
LCMV-WE replicated to significantly higher viral titers early in infection at 12 and
24 hpi, compared to titers found with LCMV-WE infection alone. By 36 hpi,
LCMV-WE was reaching peak titers in TNF-α stimulated cells.

However, in

unstimulated cells, LCMV-WE kinetics were continuing to displaying exponential
replication from 24 to 36 hpi. Analysis of LCMV-ARM replication with TNF-α
stimulation in the bottom graph of Figure 4B, showed that regardless of TNF-α
stimulation, similar titers were observed for LCMV-ARM from 12 to 24 hpi. By 36
hpi, however, LCMV-ARM titers continued to grow reaching significantly higher
titers than those observed in TNF-α-stimulated cells. Thus, with the addition of
TNF-α, LCMV-ARM replicated similarly to LCMV-ARM alone, until late in
infection. Yet, the addition of TNF-α with LCMV-WE resulted in more efficient
replication and enhanced viral titers compared to LCMV-WE without TNF-α.
These results suggest TNF-α stimulation of AML-12 hepatocytes, which we
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showed induces proliferation (Figure 3B),

also promotes LCMV-WE viral

replication.

5. TNF-α stimulation with LCMV-WE infection induces G1/S phase cell cycle
mediators and non-conventional receptor in AML-12 hepatocytes
Arenaviruses like LASV and LCMV-WE cause severe infections
characterized by an induction of pathological hepatocyte proliferation, which is an
exaggerated, pathological response in view of the mild damage caused by these
viruses [26, 29, 30, 42, 45]. Furthermore, liver hyperplasia was not evident in
human LF cases nor in NHP or murine animal models of LF-like disease,
suggesting hepatocyte cell cycle is incomplete [25, 26, 45].

Thus, we next

investigated the effect of LCMV infection on cell cycle mediators in our
proliferating AML-12 hepatocytes.
Using TNF-α stimulation to induce hepatocyte proliferation in AML-12
hepatocytes (data shown in Figure 3B), cell cycle mediators involved in
regulating G1/S phase progression were assessed after LCMV infection (Figure
5). Gene expression changes in cell cycle mediators were examined using RTPCR analysis, with fold mRNA induction normalized to Gapdh (endogenous
control) and relative to mock-infected (negative control). As seen in Figure 5A,
cyclin-dependent kinase 6 (Cdk6) and cyclin D, important regulators of cell cycle
progression at G1 to S phase, were examined first. TNF-α stimulation without
virus in AML-12 hepatocytes, the positive control condition for active cell cycle,
resulted in a modest 2-fold increase in Cdk6 mRNA at 36 hpi, but cyclin D levels
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Figure 5. TNF-α stimulation with LCMV-WE infection induces G1/S phase
cell cycle mediators and non-conventional receptor in AML-12 hepatocytes.
Growth-arrested AML-12 were stimulated with TNF-α (200 ng/mL) and infected
with LCMV-WE or LCMV-ARM at 0.1 MOI for 1 hr at 37°C. Cells were washed
and incubated in 5% FBS media containing TNF-α until termination at the
indicated hpi. Cells were collected at indicated times for RNA isolation. cDNA
was made and analyzed for cyclin D and Cdk6 (A), p53 and p21 (B), and Axl
receptor (C) using real-time RT-PCR. mRNA levels were graphed as fold mRNA
normalized to Gapdh endogenous control and relative to mock-infected negative
controls (not shown, but are equal to 1-fold), as described in Materials and
Methods. Data presented as means ± S.E.M of technical replicates, n=3. *,
indicates significance (P<0.05), between ARM and ARM + TNF-α, or WE and
WE + TNF-α, using Student’s t-Test.
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were unchanged and similar to mock-infected controls at each time point.
Upregulation of both Cdk6 and cyclin D mRNA was, however, observed with the
addition of LCMV-ARM infection, with most significant changes occurring at 36
hpi with 4- and 2-fold upregulation, respectively, of these genes. Interestingly,
when TNF-α was added to LCMV-ARM infection, mRNA levels of both Cdk6 and
cyclin D at 36 hpi were reduced closer to background levels of controls.
Generally, LCMV-WE infection, induced gene expression of both cell cycle
regulators close to 3-fold over control conditions by 36 hpi. With the addition of
TNF-α to LCMV-WE infection, however, Cdk6 levels were similar and cyclin D
levels were significantly higher than those mRNA levels with LCMV-WE infection
alone. Furthermore, induction of both Cdk6 and cyclin D at 36 hpi was also
associated with peak viral titers for LCMV-WE with and without TNF-α and for
LCMV-ARM infection alone (Figure 4B). To summarize, these gene expression
data suggest LCMV infection induces G1 cell cycle regulators; however, with the
addition of TNF-α to LCMV infection revealed stark differences in LCMV-ARM
versus LCMV-WE to induce these cell cycle regulators.
We next examined G1 cell cycle progression with TNF-α stimulation and
LCMV infection in AML-12 hepatocytes by analyzing gene expression of p53 and
p21 cell cycle inhibitors (Figure 5B). TNF-α stimulation without virus infection
showed similar p53 and p21 gene expression profiles as that found with mockinfected controls.

As observed in Figure 5B, LCMV-ARM infection, with or

without TNF-α stimulation, did not significantly alter levels of p53. In contrast,
LCMV-WE infection induced p53 mRNA, especially at 36 hpi. However, with
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TNF-α, LCMV-WE significantly induced p53 levels at 24 and 36 hpi compared to
LCMV-WE infection alone.

Furthermore, p21 mRNA levels were significantly

induced with LCMV-ARM infection alone at 36 hpi 2-fold over LCMV-ARM with
TNF-α and 3-fold over mock-infection controls. This induction was not found with
LCMV-ARM and TNF-α stimulation at 36 hpi, as p21 levels were unchanged
compared to mock-infected control. With LCMV-WE infection alone, p21 mRNA
was robustly induced at 36 hpi 5-fold over control cells, which was significantly
(i.e. 1.5-fold) greater than p21 induction observed with TNF-α and LCMV-WE
infection. Though this p21 induction with TNF-α and LCMV-WE infection was
less than that observed with LCMV-WE alone, p21 levels were still over 3-fold
greater than levels in control conditions. Thus, TNF-α stimulation with LCMV-WE
only minimally reduced p21 levels; while, TNF-α stimulation with LCMV-ARM
considerably reduced p21 closer to background, control levels. Overall, these
data demonstrated evidence of G1/S phase cell cycle arrest with upregulation of
p21 inhibitor in LCMV-WE-infected cells regardless of TNF-α stimulation and this
p21 upregulation was also associated with high levels of LCMV-WE viral
replication.
We also looked at gene expression of Axl, a receptor tyrosine kinase and
non-conventional receptor for LCMV and LASV entry into host cells [74]. Our
recent studies showed Axl to be upregulated at the gene and protein expression
levels in the liver of LCMV-WE-infected mice [45]. As a potential viral entry factor
into hepatocytes and a key player involved in inhibiting TLR-immune responses
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[75], we examined the impact of TNF-α and LCMV infection on gene expression
of Axl in AML-12 hepatocytes (Figure 5C).
Similar to its effects on cell cycle mediators’ gene expression, TNF-α
stimulation alone without virus infection did not alter Axl gene expression and
was similar to mock-infected controls, as shown in Figure 5C.

LCMV-ARM

infection alone only induced Axl mRNA at 36 hpi, which was 3-fold over controls
and 1.5-fold greater than levels observed with LCMV-ARM and TNF-α.
Interestingly, LCMV-ARM with TNF-α induced Axl mRNA levels at 24 hpi 2-fold
over controls and these levels were significantly greater than those found with
LCMV-ARM alone.

While LCMV-WE infection showed greater than 2-fold

increases in Axl mRNA by 36 hpi, LCMV-WE with TNF-α stimulation robustly
induced Axl levels earlier, 2-fold at 24 hpi, and later, 5-fold at 36 hpi, over
controls. Thus, with TNF-α, Axl levels were induced greater than 2.5-fold with
LCMV-WE infection compared to LCMV-WE infection alone by 36 hpi.
Altogether, significant changes in Axl gene expression were found late in LCMV
infection and most robust when TNF-α stimulation was coupled with LCMV-WE
infection. These increases in Axl expression with LCMV-WE infection potentially
suggest viral manipulation of host cell machinery to increase production of its
receptor, thus increasing viral entry points into the cell.

6. High viral load and upregulated pro-inflammatory IL-6 cytokine
correlated with cell cycle arrest in livers of NHPs fatally-infected with LASV
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Finally, to correlate these in vitro findings regarding LCMV-WE-induced
cell cycle arrest in AML-12 hepatocytes with an in vivo model, we examined liver
tissue from NHPs (i.e. marmosets) fatally- and non-fatally-infected with LASV.
We analyzed viral loads and gene expression profiles of liver tissue samples
from non-fatal marmoset #10 and fatal marmosets #11 and #12 for changes in
IL-6, cyclin D, p53, p21, and AXL gene expression using RT-PCR (Figure 6).
Fatal LASV infection in diseased marmosets was characterized by high
viral load in the livers of #11 and # 12, with over 10,000 copies of viral RNA per
µg of tissue, as shown in Figure 6A. Furthermore, these high viral loads were
also correlated with robust increases in pro-inflammatory cytokine IL-6, as liver
tissue from #11 showed over 800-fold mRNA induction over non-fatally-infected
#10. However, only mild IL-6 increases were observed for #12 at 6-fold over
control marmoset.
Cyclin D mRNA levels were examined in Figure 6B to look at the degree
of hepatocyte proliferation, though this was not a complete assessment of
proliferation. Liver tissue from #12 showed moderate Cyclin D elevation at 5-fold
over non-fatal marmoset #10, but this increase was not observed in #11, which
showed expression similar to control #10. We have already observed high viral
load, robustly upregulated IL-6 and mild increases in Cyclin D levels, suggesting
efficient viral replication, dysregulated liver function and pathological hepatocyte
proliferation.

Next we determined if these pathologies also correlated with

evidence of incomplete cell cycle in the livers of fatal LASV infection—as we
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Figure 6. High viral load and upregulated pro-inflammatory IL-6 cytokine
correlated with cell cycle arrest in livers of NHPs fatally-infected with LASV.
Marmosets were challenged with LASV and marmoset #10 survived (non-fatal)
and #’s 11 and 12 died (fatal). Liver tissues samples were analyzed for changes
in mRNA levels using real-time RT-PCR. Gene expression levels were assessed
for: (A) viral RNA and IL-6, (B) Cyclin D and p21, and (C) AXL. mRNA levels
were normalized to 18S endogenous control and relative to those of non-fatal
marmoset #10. Viral RNA was detected with primers specific to LASV-NP and all
primers were purchased from Life Technologies.
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demonstrated with LCMV-WE in AML-12 hepatocytes (Figure 5B) and previously
with LCMV-WE-infected mice [45]. Thus, gene expression of cell cycle inhibitor,
p21, was characterized.

Interestingly, as shown in Figure 6B, robust

upregulation of p21, greater than 30- and 20-fold, was observed in #11 and #12,
respectively, over the expression found in #10 control.

These results

demonstrate cell cycle arrest and p21 play important roles in pathogenicity of
fatal disease caused by LASV. These results also confirm the in vitro results we
found here with LCMV-WE infection in AML-12 hepatocytes. In summary, high
levels of viral RNA, pro-inflammatory IL-6, and robust increases in p21 were
characteristic of liver tissue from fatal LASV infection in marmosets.
Lastly, we tested liver tissue for changes in gene expression of a nonconventional viral receptor, AXL. As shown in Figure 6C, liver tissue from #12
showed elevated AXL expression, >4-fold higher than #10 control.

AXL

expression in #11 liver, however, displayed levels similar to control.

AXL

expression examined here did not show a clear trend in these fatally-infected
liver tissue samples, though AXL may still play an important role in LASV and
LCMV-WE

pathogenic

mechanisms
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within

severe

infections.

DISCUSSION
Pathological hepatocyte proliferation and high viral load in liver tissue are
associated with severe OW arenavirus (i.e. LASV and WE) infections. Thus, our
overall objective was to examine the effect of arenavirus-induced hepatocyte
proliferation on viral replication and cell cycle progression. To study this, we
used well-studied cell lines, murine RAW 264.7 macrophages to represent KCs
of the liver and murine AML-12 hepatocytes. LCMV-WE replicated efficiently in
RAW 264.7 macrophages and led to significant induction of TNF-α and IL-6
proinflammatory cytokines. Next, TNF-α and its effect on nearby hepatocytes
was analyzed and we found that TNF-α-stimulated AML-12 hepatocytes infected
with LCMV-WE resulted in enhanced viral replication compared to LCMV-WE
infection alone. Significant enhancement of viral replication also correlated with
induction of cell cycle mediators indicative of G1 phase and cell cycle arrest.
Building on these in vitro findings and patterns previously noted in NHPs [26, 42]
and mice [45], liver tissue taken from marmosets fatally infected with LASV also
showed high viral load, robust induction of IL-6 mRNA, and active cell cycling
with evidence of arrested cell cycle at G1/S phase.
Differences in replication kinetics and titers between LCMV-WE and
LCMV-ARM were characteristics of infection in murine macrophages and
hepatocytes (Figure 1). These replication differences between LCMV-WE and
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LCMV-ARM have been noted in different in vitro cell models used in this lab and
are also highly repeatable. Several reasons for replication differences between
LCMV-WE and LCMV-ARM are possible. LCMV has been extensively studied in
research settings.

The LCMV-ARM strain was passed through experimental

mice many times and thus, is well-adapted to mice and considered the
neurotropic strain (targets nerve cells). However, LCMV-WE is considered the
viscerotropic strain, targeting macrophages, dendritic cells, and endothelial cells,
among others, for infection in host tissues. It is reasonable that LCMV-WE is
able to more efficiently replicate in tissue cells like hepatocytes. Furthermore,
LCMV-WE and LCMV-ARM share 84% and 91% homology at the nucleotide and
amino acid sequence levels [39]. However, these viruses differ in pathogenic
potential, and in affinity for cellular receptor [76].

Differences in affinity for

cellular receptor to enter host cell also can provide an explanation of differences
in replication kinetics. While use of α-DG is the preferred method of host entry
for the virus, research has shown LCMV strains have varying affinities for α-DG.
LCMV-WE (WE 54), the pathogenic strain, for example, displays higher affinity
for α-DG than the non-pathogenic strain, LCMV-ARM, which demonstrates low
affinity [76].

Similarly, LASV GP1 has 2 logs higher affinity to α-DG in

comparison with LCMV-ARM. Thus, it is possible that LCMV-WE is entering the
host cell more quickly because it binds the receptor with greater affinity, is
internalized more quickly, and thus LCMV-WE may have a “head-start” in
replicating too.

44

It is well-documented that OW arenavirus infection, like fatal LASV,
characteristically evades detection and suppresses innate and adaptive immune
responses, reviewed in [4]. This is contrary to the “cytokine-storm” prompted by
filoviruses like Ebola virus or by NW arenavirus Junin virus, reviewed in [4].
Studies on LF disease in humans and on NHPs experimentally-infected with
LASV or LCMV-WE have shown a late-stage, pro-inflammatory profile with
severe infections, which highlights IL-6 as a biomarker in terminal disease stages
[26, 27, 43, 53] and it is also shown in early disease development [43]. Thus, in
vivo, pro-inflammatory cytokine profiles differ depending on stage of disease and
clinical outcome of disease. However, our in vitro results shown here (Figure 1A,
Figure 2) that replication of LCMV-WE induced TNF-α and IL-6 mRNA. These
results differ from previous in vitro studies that support an immunosuppressive
phenotype of pathogenic OW arenavirus infections in human monocyte-derived
macrophages.

For example, it was demonstrated that productive LASV and

LCMV-WE infections resulted in suppressed proinflammatory responses (i.e. IL6, TNF-α, or IL-8), while non-pathogenic arenaviruses, MOPV and LCMV-ARM,
showed an upregulation of proinflammatory response [22, 26, 62, 63].
Pathogenic OW arenaviruses do not activate macrophages [63], and LASV,
LCMV-WE, and Clone 13 (immunosuppressive derivative of LCMV-ARM strain)
were shown to inhibit the TLR2/Mal-dependent production of cytokines that the
non-pathogenic LCMV-ARM and MOPV did in fact stimulate with productive
replication [62]. Therefore, in vitro data regarding pro-inflammatory response
induced by pathogenic OW arenaviruses seem to differ according to cell species
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used (e.g. human versus murine), the techniques or assays used for analysis,
and also parameters of experiments and what hypotheses were used to guide
experiments.
Though these results are at-odds with our current findings that show
LCMV-WE replication is associated with both IL-6 and TNF-α production, it is
potentially explainable by the use of different cell types—we used murine cells
and previous studies used human cells. Differences between the responses of
murine and human/NHP immune systems are exemplified in the unexpected proinflammatory results from the livers of LCMV-WE experimentally-infected mice
[45]. IL-6 was expected to be robustly up-regulated, as it was in NHPs liver
tissue and plasma with severe LCMV-WE infection. Instead, IL-6 was mildly upregulated and TNF-α pro-inflammatory mediator was robustly induced, which
also was associated with characteristic OW arenavirus-induced liver pathology of
spotty necrosis, pathological hepatocyte proliferation, and increased viral
replication [45].

Furthermore, it is important to highlight that LCMV’s natural

reservoir host is Mus musculus, the house mouse. It has co-evolved with this
host and its immune system causing low level infection without inducing disease
in the mouse. Therefore, it is reasonable to conclude that the pro-inflammatory
cytokines resulting from LCMV infection in its host may not align with the profiles
observed in NHPs or in humans with LASV infection.
Building on the TNF-α cytokine response observed from LCMV-WE
infection in RAW 264.7 macrophages, we used this virus-induced TNF-α signal to
stimulate hepatocyte proliferation in vitro and then look at the impact of actively
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cycling hepatocytes on LCMV-WE’s replication kinetics. This two-hit model was
set-up to mimic and investigate the liver pathologies caused by OW
arenaviruses.

Two-hit experimental models are commonly employed in liver

research to study mechanisms of injury and oftentimes include LPS as a second
hit to exacerbate damage from a first hit (e.g. alcohol, high-fat diet, high-dose
toxins, etc.). Furthermore, models of liver regeneration have shown support for
enteric LPS being the stimulus for KCs to produce pro-inflammatory triggers (i.e.
TNF-α and IL-6) involved in prompting hepatocyte proliferation [58, 59].
However, both our in vitro research shown in this work and, as mentioned above,
previous in vivo models have demonstrated high levels of these pro-inflammatory
triggers

of

hepatocyte

proliferation

associated

with

robust

pathological

hepatocyte proliferation and high levels of OW arenavirus infection.

More

recently, Campbell et al. has provided evidence demonstrating that proinflammatory signals necessary for successful liver regeneration were dependent
on MyD88 signaling pathway, and not on pathways downstream of Cd14, TLR2,
and TLR4—the LPS receptor on KCs [61].

Research from this group has

demonstrated in human macrophages that pathogenic OW arenaviruses like
LASV and LCMV-WE inhibit TLR2/Mal-dependent pro-inflammatory cytokine
responses, and non-pathogenic counterparts, MOPV and LCMV-ARM, enhanced
these pro-inflammatory responses via this pathway [62]. Thus, it seems possible
that different species, human versus murine, respond differently to the virus,
especially considering that LCMV’s reservoir host is a rodent, as mentioned
above. Additionally, we also found robust increases in TNF-α and not IL-6 in liver

47

tissue from LCMV-WE-infected mice [45], which is generally opposite to the proinflammatory profiles found in humans [53] and NHPs [26, 27] infected with
pathogenic OW arenaviruses.
In the studies shown here, TNF-α stimulation of AML-12 cells results in
enhanced LCMV-WE viral replication, while LCMV-ARM replication was
unaffected by TNF-α (Figure 4B). TNF-α is a pleiotropic cytokine responsible for
diverse biological effects in the liver, including apoptosis, survival, and
proliferation [68]. One critical role of TNF-α in the liver, along with IL-6, upon
release from KCs is its early involvement in triggering hepatocyte proliferation
[55, 56, 60]. TNF-α can cause toxicity and cell death in high concentrations,
reviewed in [64, 65]. In the in vitro experiments shown in this thesis, we used a
supra-physiological concentration of TNF-α at 200 ng/mL to obtain a maximized
effect on the confluent and growth-arrested conditions of the AML-12
hepatocytes used in these experiments. Though, it has been shown that 20
ng/mL TNF-α treatment in hepatic in vitro cells can induce DNA synthesis [70,
73]. We modified these protocols using a higher TNF-α concentration, which,
however, is higher than that produced by LCMV-WE-infected RAW 264.7
macrophages.

Furthermore, Fletcher et al. showed that with increasing

concentrations of TNF-α (i.e. 10, 100, 1000 ng/mL) there was a correlated TNFdependent increase in hepatitis c virus (HCV) and LASV-psuedotyped-particle
virus infectivity in polarized HepG2 [77]. However, another group using Huh7
human hepatoma cells found TNF-α stimulation (at physiologically low
concentration) alone or in combination with IFN did not positively or negatively
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impact replication of LASV or LCMV-WE [78].

Recently, a group showed

enhanced LCMV-WE viral load in livers from mice experimentally-induced to
develop inflammation via a murine hepatic ischemia/reperfusion model [79]. They
concluded that inflammation resulting from TNF-α and LPS enhanced expression
of the interferon stimulated gene (ISG) ubiquitin-like protease 18 (USP18) in
hepatocytes, which was then associated with the enhanced replication of LCMVWE. Their proposed mechanism of enhanced replication is linked to increased
expression of USP18, which disrupts hepatocytes’ ability to respond to IFN-α.
Cell cycle mediators of G1 phase, cyclin D and Cdk6, were upregulated in
TNF-α-stimulated and LCMV-WE-infected AML-12 hepatocytes. The G1 phase is
rich in translational activity to produce proteins needed to prepare the cell for
DNA synthesis in S phase.

This resource-rich environment could provide

obvious benefits for replicating viruses in need of host cell machinery. Past in
vitro data has shown LCMV infection can indeed impact cell cycling factors.
HeLa cells transfected with the Z protein of LCMV, resulted in decreased protein
production of cyclins D and E [80]. Decreased D- and E-type cyclins results in a
lack of progress through G1 phase to S phase, which was evident in our findings
with increases in p21, an indicator of cell cycle arrest. Furthermore, we did not
examine protein levels of these cell cycle mediators or look at cyclin E, so it is
unclear if our in vitro system would show similar decreases in protein levels. It
was previously demonstrated that PRH/HEX, the proline-rich homeodomain
protein or hematopoietically expressed homeobox, is down-regulated in human
hepatoma cells (i.e. HepG2 and Huh7) and also in the livers of LCMV-WE-
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infected NHPs [81]. Under normal conditions, PRH/HEX functions in liver cells to
resist proliferation, by blocking the activity of cell cycle mediators involved in G 1
phase progress. This protein nor its gene expression was examined in our work,
but it seems likely that a decrease in the PRH/HEX protein would be noted early
in the G0 to G1 phase of cell cycle when the cells come out of growth-arrest and
begin to cycle.
Arenaviruses like LASV and LCMV-WE cause severe infections
characterized by an induction of pathological hepatocyte proliferation, which is an
exaggerated, pathological response in view of the mild damage caused by these
viruses [26, 29, 30, 42, 45]. Furthermore, liver hyperplasia was not evident in
human LF cases nor in NHP or murine animal models of LF-like disease,
suggesting hepatocyte cell cycle is incomplete [25, 26, 45]. Furthermore, we
recently showed that LCMV-WE infection in mice not only induced pathological
hepatocyte proliferation, but robust increases in G1/S arrest marker, p21 were
also observed at the mRNA and protein levels [45]. These results indicated,
pathological hepatocyte proliferation was arrested via p21 cell cycle inhibitor at
the G1 to S phase transition. Results from this work with TNF-α stimulated and
proliferating AML-12 hepatocytes infected with LCMV-WE showed increases in
gene expression of cell cycle inhibitor, p2 (Figure 5B). This was also confirmed,
robust p21 mRNA upregulation, in liver tissue from marmosets fatally-infected
with LASV (Figure 6B). An important regulator of hepatocyte proliferation, p21 is
controlled by p53-dependent and –independent mechanisms and can also be
regulated by mitogens and growth factors [82, 83]. Furthermore, IFNγ could play
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a role in the strong induction of p21, as IFNγ was also robustly upregulated in
LCMV-WE-infected mice [45] and can signal to induce cell cycle arrest in the liver
via p21, reviewed in [84]. p21, however, normally has a quick turnover rate in the
cell (i.e. t1/2 of ~30 min.), reviewed in [52], and our in vitro results showing high
levels of mRNA induction, as well those mRNA levels observed in marmosets
and mice, indicate that p21 is not being degraded, but potentially transcripts are
being stabilized. Respiratory syncytial virus has been shown to cause G 1 cell
cycle arrest to increase viral replication by a p53-dependent pathway, which also
resulted in accumulation of p21 [47, 85]. More extensive and focused in vitro
research is required to determine the role of p21 and cell cycle arrest as a
potential pathway to block and reduce infection.
Axl, an additional receptor for LASV and LCMV [74], was significantly
upregulated in LCMV-WE-infected AML-12 hepatocytes stimulated with TNF-α
(Figure 5C).

We also showed in a surrogate model of LF hepatitis in mice

infected with LCMV-WE that Axl was significantly upregulated at the mRNA and
protein levels in liver tissue [45]. Furthermore, our in vitro findings here that
showed elevated Axl mRNA levels with LCMV-WE infection were also confirmed
in vivo in liver tissue of fatally-infected marmosets with LASV (Figure 6C).
Together these data demonstrate that upregulation of Axl is a shared mechanism
among pathogenic arenaviruses LASV and LCMV in vitro and in vivo. However,
previous research by Sullivan et al. complicates this idea, as this group used
LCMV Clone 13 infection in Axl knock-out mice and showed no difference in viral
replication kinetics between Axl knock-out and wild-type mice and concluded that
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Axl was not needed for productive LCMV infection in mice [86]. While this group
used a different LCMV strain than we used in our vitro and murine in vivo
research, their research along with our results, could highlight that the
upregulated Axl we have observed during LCMV infection is potentially an
indirect effect of the virus and not directly used by the virus as a cellular receptor.
Or it is possible that LCMV Clone 13 does not have the same affinity for Axl
receptor as LCMV-WE or LASV, so it does not depend on this cellular receptor
for host cell entry and replication. Axl, as a receptor tyrosine kinase, has many
different roles in cells throughout the body, including cell-cell communication,
survival, proliferation and regulation of immune response, reviewed in [87].
Increases in Axl expression could be a mechanism to promote viral replication in
the liver, as Axl plays an important role in the liver (along with fellow Tyro3 and
Mer receptors) in inhibiting TLR-mediated immune response [75] to maintain
immune-tolerance [88]. As previous research has showed, Axl is also used by
LASV and LCMV as an alternate receptor, besides the conventional receptor αdystroglycan [20], to enter host cells [74]. Thus, increasing Axl expression is an
important arenavirus mechanism that requires investigation, as it potentially
provides more detail to how such high viral loads are produced in the liver,
without detection by the immune system.
In this work we have demonstrated that arenavirus infection of
macrophages and hepatic cells itself can stimulate cytokine pro-inflammatory
response, promotes virus replication and affects cell-cycling machinery. In line
with in vitro observations and previous murine in vivo results, we have found up-
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regulation of pro-inflammatory cytokines and cell cycling genes in liver tissues of
marmosets fatally-infected with LASV. Taken together with previous observations
in NHPs and in a murine model of transient arenavirus hepatitis we suggest that
failure of proper hepatocyte proliferation results in pathophysiological events (i.e.
apoptosis, over-production of IFN-gamma, oval cells, etc.) causing major liver
dysfunction, as it was demonstrated in an NHP model of arenavirus-induced liver
pathology.
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SUMMARY AND CONCLUSIONS
Strengths of this work
The results presented in this thesis have many strengths. First, the results
observed here demonstrate that we developed and characterized an in vitro
model with RAW 264.7 macrophages and AML-12 hepatocytes that supports in
vivo findings from arenavirus-induced hepatitis and can be used for further study
to determine specific arenavirus mechanisms. LCMV-WE infection in these cells
support data previously observed in experimental animal models: arenavirusinduced pro-inflammatory response, hepatocyte proliferation, enhanced viral
replication, and evidence of cell cycle arrest. Development of this in vitro model
capable of recapitulating in vivo data is a critical finding for future efforts to
investigate mechanisms of arenavirus-induced liver pathology, including
mechanisms of: robust viral replication, evasion of host immune response, and
cell cycle arrest in cycling hepatocytes. These viral mechanisms are critically
involved in progression of disease towards unregulated, systemic infection.
Thus, the ability to investigate how the virus mechanistically increases infection
and evades immune detection in relevant in vitro models will lead to a better
understanding of how to inhibit these viral mechanisms, and thus will facilitate
development of effective anti-viral therapeutics to control or prevent disease.
Furthermore, we showed upregulation of pro-inflammatory cytokines TNF
and IL-6 with LCMV-WE infection in RAW 264.7 macrophages, which is the first
example in the literature demonstrating an arenavirus directly induces this profile
of pro-inflammatory cytokines after infection.
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This TNF-α and IL-6 cytokine

profile, in particular, is important for early events triggering hepatocyte
proliferation, which provides a potential mechanism for how arenaviruses are
able to trigger the characteristic pathological hepatocyte proliferation during
severe infection.

Unanswered questions and future directions
What role do TNF-α and IL-6 play in arenavirus-induced liver pathology?
High levels of serum IL-6 were found in human LF patients with poor
prognoses and thus, IL-6 levels were correlated with disease severity [53, 89].
However, serum TNF-α levels were not found to be elevated in patients with fatal
or nonfatal LF disease [89]. Arenavirus infection in NHP animal models also
resulted in high levels of IL-6 in the sera and in liver tissue, as well as elevated
levels of receptors for IL-6 and TNF in the sera [26, 27, 43]. Contrary to what
was expected, LCMV-WE infection in experimentally-infected mice correlated
with robust induction of TNF mRNA in liver tissue, while only mild induction of IL6 mRNA was found. Though there is a similar pattern of liver pathology found in
these arenavirus infections—which includes high levels of pro-inflammatory
cytokines, robust pathological hepatocyte proliferation, and liver being the tissue
with highest viral load—there are major differences in the profiles of proinflammatory cytokines induced with infection.
To further complicate the story, the results presented in this work
demonstrated LCMV-WE infection in macrophages directly induced TNF-α gene
expression and protein production. Building on these results, TNF-α stimulation
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in addition to LCMV-WE infection in AML-12 hepatocytes led to enhanced viral
replication, actively cycling hepatocytes, and evidence of cell cycle arrest. Thus,
here it was determined that in murine in vitro models infected with LCMV-WE,
TNF-α is a critical pro-inflammatory cytokine involved in triggering pathological
hepatocyte proliferation and also critically involved in enhancing viral replication.
Based on these in vitro results plus data from liver tissue of LCMV-WE-infected
mice compared to results from NHPs and human LF disease, it seems
reasonable to hypothesize that TNF is yet an important cytokine in arenavirus
infections, but two major THINGS are responsible for differences in its production
profile in different models: 1) Timing of TNF-α release and function precedes
severe disease state, 2) Extent of viral replication, and 3) Human versus rodent
immune system.
In future experiments, it will be important to further characterize the role
TNF-α plays in arenavirus infection in hepatocytes, particularly the signaling
events and mediators downstream of TNF-α binding its primary receptor, TNFRI.
If this receptor is blocked

How do arenaviruses infect hepatocytes in vitro and in vivo?
In spite of the fact that hepatocytes are not known to express the
canonical OW arenavirus receptor, α-DG, numerous animal studies [26, 44, 45]
and human clinical findings [29, 30] have shown the liver and specifically,
hepatocytes, have a high viral burden. As noted above, and in the work shown
here, arenavirus infections not only trigger pathological hepatocyte proliferation,
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but also cell cycle arrest in G1 phase.

This host response of hepatocyte

proliferation provides key resources needed for viral replication, like increased
protein production, cell cycle factors, and energy.

Furthermore, proliferating

hepatocytes display more of an embryonic phenotype, which may include the
expression of the canonical OW arenavirus receptor, α-DG. α-DG is expressed
in embryonic or developing tissues [90] and expression diminishes in adult,
differentiated tissues [91, 92]. Therefore, adult, differentiated hepatocytes are
not known to express glycosylated α-DG.

Yet, the highest viral load during

infection is found in the liver and in hepatocytes, according to findings from
animal studies [26, 27, 44, 45] and human clinical data [29, 30].

This is

potentially a viral mechanism to provide new substrates for increased infection.
Thus, it is not clear how the virus infects hepatocytes in vivo or in vitro.
Some unpublished results from this lab have shown positive staining for α-DG on
human hepatoma cells, HepG2, and the murine hepatocyte cells used here,
AML-12. While use of α-DG is the preferred method of host entry for the virus,
research has shown LCMV strains have varying affinities for α-DG. LCMV-WE,
the pathogenic strain, for example, displays higher affinity for α-DG than the nonpathogenic strain, LCMV-ARM, which demonstrates low affinity [76].

Non-

conventional receptors, like Axl described in this work, also have been used for
OW arenavirus cell entry.

Future studies are needed to determine the

receptor(s) used in attachment to hepatocytes and the routes taken in entry
steps. These early entry details will have important implications for host immune
response and viral replication efficiency.
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What is the role of cell cycle and cell cycle arrest in productive arenavirus
infection?
We show here that AML-12 hepatocytes are a useful in vitro model to
further investigate mechanisms involved in pathological hepatocyte proliferation,
including cell cycle arrest, and efficient pathogenic arenavirus replication. Many
experiments still need to be performed to provide a better understanding of
arenavirus-induced liver pathology, but the results shown here indicate the future
directions to pursue next need to answer the questions: 1) Are the changes in
gene expression of cell cycle mediators carried through to changes in protein
levels as well? 2) If p21 or p53 are inhibited with siRNA, and thus not able to
arrest cell cycle so that cells will continue to cycle into S phase, then what impact
will this have on LCMV-WE viral replication—will it be significantly decreased?
What is role of p21 and cell cycle arrest in enhancing arenavirus infection? Does
the virus use p21 directly to facilitate viral replication or does the virus indirectly
allow p21 mRNA to accumulate because the virus uses a molecule related to p21
degradation for viral replication?

Thus, taken together, it is important to

investigate the mechanisms behind the robust increase in p21 in LCMV-WEinfected mice and murine hepatocytes and to determine the effect cell cycle
manipulation has on viral replication and the effect the virus has on cell cycle as
well.

Conclusions
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This work has demonstrated that LCMV infection in in vitro macrophages
produces high viral titers resulting in production of pro-inflammatory cytokines
involved in hepatocyte proliferation.

LCMV infection and TNF- cytokine

stimulation of in vitro hepatocytes together displayed enhanced viral replication
and altered cell cycle progression, with evidence of arrest. In good confirmation
with these in vitro observations, we correlated high viral load and elevated proinflammatory IL-6 with robust increases in p21 as evidence for cell cycle arrest in
liver tissue of marmosets fatally-infected with LASV. Taken together with
previous observations in NHPs and in a murine model of transient arenavirus
hepatitis we suggest that failure of proper hepatocyte proliferation—as observed
with elevated cell cycle inhibitor p21 which is evidence of cell cycle arrest—
results in pathophysiological events (i.e. apoptosis, over-production of IFNgamma, oval cells, etc.) causing major liver dysfunction, as it was demonstrated
in an NHP model of arenavirus-induced liver pathology.
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APPENDIX 1
ABBREVIATIONS
α-DG

alpha-dystroglycan

ALT

Alanine aminotransferase

AST

Aspartate aminotransferase

HFV

Hemorrhagic fever virus

HPI

Hours post-infection

IL-6

Interleukin-6

LASV

Lassa virus

LCMV

Lymphocytic choriomeningitis virus

LCMV-ARM Lymphocytic choriomeningitis virus, Armstrong strain
LCMV-WE

Lymphocytic choriomeningitis virus, WE strain

LF

Lassa fever

LPS

Lipopolysaccharide

MOPV

Mopeia virus

NHP

Non-human primate

NW

New World (arenavirus)

OW

Old World (arenavirus)

TNF-α

Tumor necrosis factor alpha

TNFRI

Tumor necrosis factor receptor type I

VHF

Viral hemorrhagic fever
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